1350 results for Leukemia
Refine Your Search
Subaru Celebrates Ten Years Partnering with The Leukemia & Lymphoma Society
Subaru Celebrates Ten Years Partnering with The Leukemia & Lymphoma Society To Support Nearly , Cancer Patients and Families NationwideAutomaker provi…
News Release
Niclosamide for the Treatment of Relapsed/Refractory Pediatric Acute Myeloid Leukemia
Niclosamide is an FDA approved drug that is well tolerated and acts synergistically with chemotherapy to kill AML cells. We will conduct a Phase I cl…
The Leukemia & Lymphoma Society Earns a Four-Star Rating From Charity Navigator
The Leukemia & Lymphoma Society is proud to announce that because of its strong financial health and ongoing accountability and transparency, LLS has …
News Release
Suggested Reading - Adult Leukemia: A Comprehensive Guide for Patients and Families
This guide provides an overview of many types of leukemia and explores signs and symptoms, diagnosis, tests and procedures, treatment options, as wel…
Suggested Reading - Adult Leukemia: A Comprehensive Guide for Patients and Families
This guide provides an overview of many types of leukemia and explores signs and symptoms, diagnosis, tests and procedures, treatment options, as wel…
Precision Medicine Inhibitor and Immunotherapy Approaches for High-Risk Childhood Leukemias
Dr Tasian’s scientific passion is successful development of precision medicine therapies for childhood leukemia. Her translational laboratory researc…
FDA Approves First CAR T-Immunotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
The U.S. Food and Drug Administration (FDA) recently announced approval of brexucabtagene autoleucel (Tecartus®) as the first and only CAR treatment …
FDA Approves Vyxeos for Secondary Acute Myeloid Leukemia in Children
DUBLIN, March , - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyx…
Blog
IL7 receptor-targeted CAR T-cell Therapy for T-Acute Lymphoblastic Leukemia (T-ALL)
On the basis that acute lymphoblastic leukemia () cells overexpress receptor (IL7R), which promotes chemotherapy resistance and relapse, we develope…
UCLA Health Joins The Leukemia & Lymphoma Society’s Innovative Clinical Trial
The Beat AML Master Clinical Trial is a collaboration to bring precision medicine to patients with acute myeloid leukemia and is the first clinical …
The Impact of Minimal Residual Disease in Acute Lymphoblastic Leukemia
[Click here to enlarge.] Presentation Click Here Topics Covered We invite you to learn more about: …
The Leukemia & Lymphoma Society Applauds Therapy Advances for Myeloma Patients
For Immediate ReleaseContact: Andrea GreifSenior Director of Communications()- (p))- (c)[email protected](White Plains, NY) - February , - Two re…
News Release
New Study Shows 9/11 Responders Have Higher Rates of Leukemia
All / responders put their own lives at risk to save others from the events that occurred at the World Trade Center (WTC) on September , , in New York…
Cellular Crosstalk In The Normal And Malignant Bone Marrow
We want to understand how leukemia inhibits blood production as this is one of the main causes of death in leukemia patients. We use new microscopy te…
Understanding Leukemia in Children with Down Syndrome to Develop Better Therapies
This Specialized Center of Research is focused on identifying the contributions of chromosome , which is present in three copies in individuals with D…
Developing novel therapeutic approaches for classical and variant hairy cell leukemia
In this proposal, we have combined clinical and research expertise in HCL across Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College…
Understanding the role of Metabolic Regulator SIRT5 in Acute Lymphoblastic Leukemia
p>SIRT5 is a master regulator of central energy metabolism. The survival and growth of Acute Myeloid Leukemia (AML) cells depend on SIRT5. I will e…
Research: Grants
Investigating the dependency for protein synthesis in Venetoclax/Azacitidine-resistant acute myeloid leukemia
Relapsed and/or refractory acute myeloid leukemia (AML) display resistance to Venetoclax and Azacitidine (Ven/Aza) with approximately one third of pat…
Personalized Anti-TCRVbeta2 therapeutic antibody and ADC for T Cell Leukemias and Lymphomas
T cell cancers together comprise ~% of acute leukemias and 's lymphomas. A major challenge with currently available treatments for these is that the t…
Oral Formulation of Methotrexate Now Available for Children with Leukemia Subtype
New formulation of key blood cancer treatment offers important option for children, may help with ongoing cancer drug shortages Rye Brook, N.Y., Decem…
FDA Approves Immunotherapy for Earlier Use in B-cell Acute Lymphoblastic Leukemia
Blinatumomab will now be available for adults and kids with newly diagnosed RYE BROOK, N.Y., June , – The U.S. Food and Drug Administration on Frida…
News Release
The Leukemia & Lymphoma Society Denounces Federal Actions that Threaten Cancer Patients
WASHINGTON, February , – As the nation’s largest organization serving the critical needs of blood cancer patients, we are alarmed by recent actions t…
News Release
LLS Expands its Global Master Trial for Hard-To-Treat Leukemias in Children
Marks the Global Pediatric Trial for Menin InhibitorsThe PedAL (Pediatric Acute Leukemia) Master Trial is at the heart of LLS’s Dare to Dream Project…
News Release
Targeting the interplay between signaling and transcriptional dysfunction in myeloid leukemias
Our research program is focused on understanding the intersection between signaling and transcriptional dysfunction in myeloid leukemias. We leverage …